Placental development and fetal growth in growth hormone-treated ewes.
The effects of recombinant bovine growth hormone (bGH) treatment of pregnant ewes on maternal metabolism, placental development and fetal growth were examined in two studies. In a preliminary study (experiment one), single-bearing ewes were treated by twice-daily subcutaneous injection for 7 days with bGH (n = 8) at a dose of 0.15 mg/kg LW/day or with saline (n = 8) between days 101 and 107 of gestation inclusive. In experiment two, single- and twin-bearing ewes were treated for 14 days with bGH (0.15 mg/kg L W/day) (n = 10) or saline (n = 10) between days 70 and 83 or days 98 and 111 of gestation inclusive. Ewes were killed on the day following termination of bGH treatment and fetal and placental measurements recorded. Maternal plasma concentrations of GH, IGF-I and insulin were higher (P < 0.001) in bGH-treated ewes relative to saline-treated ewes in both experiments. Consistent across experiments was an increase (P < 0.05) in the weight of the myoendometrium in bGH-treated ewes. Treatment with bGH also increased the total weight of the gravid uterus (P < 0.05) in both experiments. Weights of the uterine fluids were increased by bGH in experiment one (P < 0.05), but an effect of the same magnitude could not be repeated in experiment two. In experiment one, there was a tendency towards increased mean fetal body weights after growth hormone treatment, although the effect was non-significant. In experiment two, treatment with bGH was associated with significantly (P < 0.05) higher fetal weights, but only at the later stage of gestation (day 112). This effect was additive with that of fetal rank. Exogenous bGH treatment had little discernible effect on measures of placental size. It is concluded that administration of exogenous bGH to pregnant ewes can stimulate fetal growth, but only after about day 100 of gestation. This response seems most likely to reflect changes in maternal nutrient partitioning or placental function, rather than placental size. These studies suggest a role for growth hormone of maternal or placental origin in the regulation of fetal growth.
Jenkinson
C M
CM
Department of Animal Science, Massey University, Palmerston North, New Zealand.
Min
S H
SH
Mackenzie
D D
DD
McCutcheon
S N
SN
Breier
B H
BH
Gluckman
P D
PD
D000653:Amniotic Fluid / Q000737:chemistry; D000818:Animals; D002417:Cattle; D005314:Embryonic and Fetal Development / Q000187:drug effects / Q000502:physiology*; D005321:Extraembryonic Membranes / Q000187:drug effects / Q000502:physiology; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D009215:Myometrium / Q000187:drug effects / Q000502:physiology; D009929:Organ Size; D010920:Placenta / Q000187:drug effects / Q000502:physiology*; D011247:Pregnancy; D011994:Recombinant Proteins / Q000494:pharmacology; D012016:Reference Values; D012756:Sheep; D014599:Uterus / Q000187:drug effects / Q000502:physiology
D007328:Insulin; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone